{"id":"injection-of-nmba","safety":{"commonSideEffects":[{"rate":null,"effect":"Residual neuromuscular blockade"},{"rate":null,"effect":"Histamine release (with certain agents)"},{"rate":null,"effect":"Anaphylaxis"},{"rate":null,"effect":"Malignant hyperthermia (in susceptible patients)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NMBAs competitively or non-competitively inhibit acetylcholine receptors at the motor end plate, preventing muscle contraction. This is used during anesthesia and intubation to facilitate surgical access and mechanical ventilation. The effect is reversible and wears off as the drug is metabolized or cleared.","oneSentence":"NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:10.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation"}]},"trialDetails":[{"nctId":"NCT03196791","phase":"PHASE3","title":"Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2017-10-10","conditions":"Gastric Cancer, Obesity","enrollment":196},{"nctId":"NCT01728584","phase":"PHASE4","title":"A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-28","conditions":"Gallbladder Disease","enrollment":127},{"nctId":"NCT02004015","phase":"PHASE4","title":"Assessment Study of the Effect of NMBA on Bowel Peristalsis","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2013-11","conditions":"Physiopathology","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"injection of NMBA","genericName":"injection of NMBA","companyName":"Fondation Ophtalmologique Adolphe de Rothschild","companyId":"fondation-ophtalmologique-adolphe-de-rothschild","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction. Used for Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}